Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented final first-in-human data for ...

Replimune (REPL) won over the FDA to submit a marketing application for its lead asset RP1 for the third time despite previous rejections, thanks to the intervention of White House officials, The Wall ...

Short interest in Replimune Group Inc (NASDAQ:REPL) increased during the last reporting period, rising from 21.16M to 23.66M. This put 56.4% of the company's publicly available shares short. Based on ...

Whether it’s creating a strategy for current and future tech needs or deploying a new cybersecurity platform to protect company data, these IT consulting firms in and around Chicago are helping ...

Learn which top coins have the potential for major gains in the crypto market this year. These risks might sound hypothetical, but they are very real. In the end, the cryptocurrency community must get ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...